CL2015002181A1 - Tratamiento de formas progresivas de esclerosis múltiple con laquinimod. - Google Patents

Tratamiento de formas progresivas de esclerosis múltiple con laquinimod.

Info

Publication number
CL2015002181A1
CL2015002181A1 CL2015002181A CL2015002181A CL2015002181A1 CL 2015002181 A1 CL2015002181 A1 CL 2015002181A1 CL 2015002181 A CL2015002181 A CL 2015002181A CL 2015002181 A CL2015002181 A CL 2015002181A CL 2015002181 A1 CL2015002181 A1 CL 2015002181A1
Authority
CL
Chile
Prior art keywords
laquinimod
multiple sclerosis
treatment
progressive forms
progressive
Prior art date
Application number
CL2015002181A
Other languages
English (en)
Spanish (es)
Inventor
Nora Tarcic
Dan Bar-Zohar
Liat Hayardeny
Sherki Yossi Gilgun
Tali Gorfine
Volker Knappertz
Ella Sorani
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51351655&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015002181(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of CL2015002181A1 publication Critical patent/CL2015002181A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2015002181A 2013-02-15 2015-08-05 Tratamiento de formas progresivas de esclerosis múltiple con laquinimod. CL2015002181A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361765394P 2013-02-15 2013-02-15
US201361911106P 2013-12-03 2013-12-03

Publications (1)

Publication Number Publication Date
CL2015002181A1 true CL2015002181A1 (es) 2016-06-03

Family

ID=51351655

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015002181A CL2015002181A1 (es) 2013-02-15 2015-08-05 Tratamiento de formas progresivas de esclerosis múltiple con laquinimod.

Country Status (18)

Country Link
US (2) US20140235670A1 (OSRAM)
EP (1) EP2956137A4 (OSRAM)
JP (1) JP2016510343A (OSRAM)
KR (1) KR20150119227A (OSRAM)
CN (1) CN105163737A (OSRAM)
AU (1) AU2014216199A1 (OSRAM)
BR (1) BR112015019564A2 (OSRAM)
CA (1) CA2900503A1 (OSRAM)
CL (1) CL2015002181A1 (OSRAM)
EA (1) EA201591507A1 (OSRAM)
HK (2) HK1218251A1 (OSRAM)
IL (1) IL240014A0 (OSRAM)
MX (1) MX2015010296A (OSRAM)
PE (1) PE20151526A1 (OSRAM)
SG (1) SG11201505818WA (OSRAM)
TW (1) TW201442709A (OSRAM)
UY (1) UY35328A (OSRAM)
WO (1) WO2014127139A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015505564A (ja) 2012-02-03 2015-02-23 テバ ファーマシューティカル インダストリーズ リミティド 第一選択の抗ＴＮＥα療法に失敗したクローン病患者を治療するためのラキニモドの使用
AR090885A1 (es) * 2012-05-02 2014-12-10 Teva Pharma Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple
AU2015253330A1 (en) 2014-04-29 2016-12-01 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status
US10537566B2 (en) 2014-10-16 2020-01-21 Novartis Ag Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis
US10091217B2 (en) 2016-06-21 2018-10-02 Logrhythm, Inc. Risk based priority processing of data
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
US12370233B2 (en) 2016-08-31 2025-07-29 Mapi Pharma Ltd. Depot systems comprising glatiramer acetate
WO2018178973A1 (en) * 2017-03-26 2018-10-04 Mapi Pharma Ltd. Glatiramer depot systems for treating progressive forms of multiple sclerosis
US20230296628A1 (en) * 2020-07-09 2023-09-21 Oklahoma Medical Research Foundation Biomarkers for Identifying Relapses in Multiple Sclerosis

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
SE9801474D0 (sv) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
US7989473B2 (en) * 2006-06-12 2011-08-02 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
WO2009009529A1 (en) * 2007-07-11 2009-01-15 Medicinova, Inc. Treatment of progressive neurodegenerative disease with ibudilast
TW201014605A (en) * 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
JP2012512165A (ja) * 2008-12-11 2012-05-31 バイオヴィスタ，インコーポレイテッド 四環系ピラジノインドールを用いた多発性硬化症の治療方法
DK2442651T3 (en) * 2009-06-19 2015-09-21 Teva Pharma Treatment of multiple sclerosis with laquinimod
SG10201509831XA (en) * 2010-12-07 2015-12-30 Teva Pharma Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
JP2014521659A (ja) * 2011-07-28 2014-08-28 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドおよびインターフェロンβを組み合わせた多発性硬化症の治療
AR090885A1 (es) * 2012-05-02 2014-12-10 Teva Pharma Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple
US20140107154A1 (en) * 2012-10-12 2014-04-17 Teva Pharmaceutical Industries, Ltd. Laquinimod for reducing thalamic damage in multiple sclerosis
AU2015253330A1 (en) * 2014-04-29 2016-12-01 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status

Also Published As

Publication number Publication date
HK1218251A1 (zh) 2017-02-10
EA201591507A1 (ru) 2015-12-30
TW201442709A (zh) 2014-11-16
CN105163737A (zh) 2015-12-16
PE20151526A1 (es) 2015-11-20
MX2015010296A (es) 2016-05-05
WO2014127139A1 (en) 2014-08-21
UY35328A (es) 2014-09-30
CA2900503A1 (en) 2014-08-21
US20180064702A1 (en) 2018-03-08
JP2016510343A (ja) 2016-04-07
BR112015019564A2 (pt) 2017-07-18
AU2014216199A1 (en) 2015-09-03
US20140235670A1 (en) 2014-08-21
EP2956137A1 (en) 2015-12-23
KR20150119227A (ko) 2015-10-23
IL240014A0 (en) 2015-09-24
HK1218254A1 (zh) 2017-02-10
SG11201505818WA (en) 2015-08-28
EP2956137A4 (en) 2016-08-03

Similar Documents

Publication Publication Date Title
CL2015002181A1 (es) Tratamiento de formas progresivas de esclerosis múltiple con laquinimod.
UY34720A (es) Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fumarato de dimetilo
NI201600071A (es) Compuestos de inhibidor de autotaxina
EA201690753A1 (ru) Комбинации ингибиторов гистондеацетилазы и иммуномодулирующих лекарственных средств
CR20160308A (es) Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores
CL2016000042A1 (es) Uso de una combinación de un inhibidor de mek y un inhibidor de erk para el tratamiento de enfermedades hiperproliferativas.
GT201600027A (es) Inhibidores de rorc2 y sus métodos de uso
EP3177311C0 (en) COMBINATION OF MEDICINAL PRODUCTS CONTAINING CABOZANTINIB AND A PROTEASOME INHIBITOR FOR THE TREATMENT OF MULTIPLE MYELOMA
MX382537B (es) Combinacion de un agonista de ppar con un agonista de fxr
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
MX365321B (es) Métodos para el tratamiento de neutropenia mediante agonistas retinoides.
UY34786A (es) Procedimiento para la fabricación de una forma farmacéutica que comprende nifedipino y candesartan cilexetilo
EA201691108A1 (ru) Хиназолин-thf-амины в качестве ингибиторов pde1
MX2017010654A (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres.
PL2988750T5 (pl) Zastosowanie chlorowodorku landilolu w długotrwałym leczeniu tachyarytmii
CL2015002666A1 (es) Formas de dosificación sólidas de antiemético de liberación prolongada
UY35823A (es) Profármacos de antagonista de nmda
MX2015012455A (es) Metodo para el tratamiento de la enfermedad de higado graso.
EA201690446A1 (ru) Лечение множественной миеломы
MX381429B (es) Tricostatina a (tsa) para usarse en el tratamiento del cáncer.
BR112015016394A2 (pt) carboxamidas ii baseadas em pirazolil como inibidoras do canal crac
MX2017012449A (es) Tratamiento del dolor.
CL2015003211A1 (es) Combinación sinergística de paracetamol/celecoxib para el tratamiento de dolor inflamatorio.
BR112015019792A2 (pt) composição para tratamento de hemorróidas e método de preparação
AR094809A1 (es) Tratamiento de formas progresivas de esclerosis múltiple con laquinimod